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A B S T R A C T
The aim of this study was to compare differences in sexual behavior between patients
with benign and malignant breast tumors. A total of 187 patients treated for breast tu-
mors (benign or malignant) at the General Hospital »Po`ega«, Croatia, filled in the
questionnaire between January 2001 and May 2003. Patients were asked to fill in the
questionnaire one to ten years after treatment of breast tumor, while they were on their
regular control visit. Deterioration in sexual life experienced 36.27% of patients with be-
nign tumors and 51.76% of patients with malignant tumor (p<0.01). The main reason of
sex life impairment in both groups was distortion of body image perception. Most of
partners did not change their behavior toward women with breast tumors (48.72% for
benign group and 41.82% or malignant group, p>0.05). A great amount of women in
both groups felt certain change in her »body image«, but in greater extent in malignant
group (41.18% vs. 25.49%), (p<0.05). From our results we can see that patients in this
study do not recognize need for consultation with their physician regarding sex life after
treatment of tumor (41.18% for benign and 35.29% in malignant group). It can be con-
cluded that considerable amount of attention should be given to psychological aspects of
recovery which can improve prognosis and quality of life in general.
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Introduction
Most diseases of the breast in women
present as a palpable masses, inflamma-
tory lesions, nipple secretions, or mam-
mographic abnormalities. Although for-
tunately most are benign, cancer of the
breast is the second most common cause
of cancer deaths and one of the most
dreaded diseases of women. Benign disor-
ders of the breast include fibrocystic
changes, epithelial hyperplasia, sclerosing
adenosis, small duct papillomas and
fibroadenomas1. It is important to em-
phasize that fibrocystic changes repre-
sent the single, most common disorder of
the breast and account for more than half
of all surgical operations on the female
breast. In one study of postmortem autop-
sies, grossly evident fibrocystic changes
were present in 20% and hystopatologic
changes were present in 59% of women2.
Malignant disorders of the breast include
ductal and lobular carcinoma in situ, in-
vasive ductal and lobular carcinoma,
medullar carcinoma, colloid carcinoma,
tubular carcinoma and invasive papillary
carcinoma. As early as the sixteenth cen-
tury, rudimentary attempts to gain local
control of breast cancer were made, but
the first widely accepted operation was
introduced by Halsted in late nineteenth
centuty3.
Fibrocystic changes and fibroadenomas,
the two most common disorders of the
breast occur at any age within the repro-
ductive period of life but are more com-
mon between the ages of 20 and 40 years
of age1. The incidence of breast cancer is
negligible before age of 25, and peak inci-
dence is in seventh decade of life1. Female
sexuality is an extraordinarily complex
process. The physician needs to be aware
of the patient’s sexuality and whether or
not there are sexual concerns. Physiologic
changes over the lifespan can interact
with sexual performance as can a variety
of disease processes. Partner and rela-
tionship issues must also be taken into
account4. Women between 50 and 92, who
have a current sexual partner, attribute
at least some importance to sex, with
many rating sex as ’very’ or ’extremely’
important5.
The value of any intervention, includ-
ing those directed at women with cancer,
is determined by judging its impact on
both quantity of life and quality of life,
and it is well known that an important
aspect of quality of life is sexual function-
ing. The aim of this study was to compare
sex life of women with breast tumors, be-
fore and after treatment, to identify psy-
chological factors that influence sexual-
ity, and to determine are there differences
in sexual life between women who were
treated for benign or malignant breast
tumors.
Materials and Methods
A total of 187 patients treated for
breast tumors (benign or malignant) at
the General Hospital »Po`ega«, Croatia,
filled in the questionnaire between Janu-
ary 2001 and May 2003. Patients were
asked to fill in the questionnaire one to
ten years after treatment of breast tumor,
while they were on their regular control
visit. The questionnaire was especially
prepared for this study. Although there
are several validated sexual scales that
could have been used, it is difficult to im-
plement them into this study because of
social, economic and educational charac-
teristics of Croatia. There are 28 ques-
tions in the questionnaire. The first part
of the questionnaire asked about some
general information and the second part
was designed to investigate possible sex-
ual difficulties after breast tumor treat-
ment. To explore the differences in sexual
life, we have divided patients into two
groups: 1) patients with benign tumors
and 2) patients with malignant tumors.
Statistical difference between distribu-
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tion of answers to selected questions be-
tween these two groups of patients was
determined through the use of the 2-test.
Table 1 presents basic distribution of pa-
tients according to type of tumor, marital
status, level of education and type of
treatment. Table 2 reveals their distribu-
tion according to age at diagnosis, age at
first sexual intercourse, age at first mar-
riage, number of deliveries, number of
abortions and menstrual cycles. Table 3
presents basic distribution of patients ac-
cording to favorite parent during child-
hood and puberty, attitude towards men-
arche and attitude towards first inter-
course. Relationship with parents during
childhood and puberty, parent’s socioeco-
nomic level, parental attitudes towards
child sexuality and the openness of fam-
ily habits play an important role in sex-
ual development6,7. Timing of first discus-
sion of sexual intercourse contributes ad-
ditional variance in several sexually risky
behaviors, along with contribution of the
amount of communication with both fa-
thers and mothers8. Comfort with per-
sonal sexuality is associated with a comfort
with menstruation as a normal, publicly
acceptable event9.
Results
Table 1 reveals statistically significant
difference between two studied groups re-
garding marital status (p<0.01) and level
of education (p<0.05). Difference in mari-
tal status can be explained by differences
in age, because patients with malignant
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TABLE 1
DISTRIBUTION OF PATIENTS ACCORDING TO TYPE OF CANCER, MARITAL STATUS, LEVEL
OF EDUCATION AND TYPE OF TREATMENT. DISTRIBUTION OF PATIENTS ACCORDING TO





Type of tumor 102 85
Marital status**
Never married 9 (8.82) 3 (3.53)
Married 78 (76.47) 55 (64.71)
Divorced 4 (3.92) 2 (2.35)
Widowed 11 (10.79) 25 (29.41)
Level of education*
University degree 10 (9.80) 7 (8.24)
Completed high school 47 (46.08) 25 (29.41)
Completed elementary school 45 (44.12) 53 (62.35)
Type of treatment
Surgery# 102 (100) 60 (70.60)
Surgery#, irradiation 5 (5.88)
Surgery#, irradiation, chemotherapy 11 (12.94)
Irradiation 5 (5.88)
Chemotherapy 2 (2.35)
Irradiation, chemotherapy 2 (2.35)
* p<0.05, **p<0.01,
# Surgery procedure in benign group was lumpectomy, and in malignant modified
mastectomy.
tumors are older and more likely to be
widowed (29.41% vs. 10.79%). Patients
with benign tumors were treated surgi-
cally with lumpectomy alone, and those
with malignant tumors were treated with
modified mastectomy alone or in combina-
tion with radiation and/or chemotherapy.
From Tables 2 and 3 we can se that
there is no statistically significant differ-
ence between two groups regarding age
at first sexual intercourse, age at first
marriage, number of deliveries and abor-
tions, menstrual cycles, favorite parent
during puberty, attitude towards menar-
che and attitude towards first intercourse
(p>0.05). There was, only differences in
age at diagnosis of tumor, which is under-
standable because benign breast tumors
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TABLE 2
DISTRIBUTION ACCORDING TO AGE AT DIAGNOSIS, AGE AT FIRST SEXUAL INTERCOURSE,







 30 years 11 (10.78) 0
31–50 years 71 (69.61) 21 (24.70)
51–70 years 20 (19.61) 55 (64.71)
 71 years 0 9 (10.59)
Age at first sexual intercourse
 19 years 44 (43.14) 41 (48.24)
20–24 years 52 (50.98) 36 (42.35)
 25 years 5 (4.90) 8 (9.41)
Virgin 1 (0.98) 0
Age at first marriage
 19 years 35 (37.63) 25 (30.49)
20–24 years 42 (45.16) 46 (56.10)
 25 years 16 (17.21) 11 (13.41)
Number of deliveries
None 12 (11.77) 6 (7.06)
One 10 (9.80) 12 (14.12)
Two 59 (57.84) 44 (51.76)
Three 10 (9.80) 14 (16.47)
Four and more 11 (10.79) 9 (10.59)
Number of abortions
None 64 (62.75) 43 (50.59)
One 20 (19.61) 22 (25.88)
Two 13 (12.75) 14 (16.47)
Three 2 (1.96) 3 (3.53)
Four and more 3 (2.93) 3 (3.53)
Menstrual cycles
Regular 82 (80.39) 74 (87.06)
Irregular 20 (19.61) 11 (12.94)
** p < 0.01
appear in younger age groups1. Favorite
parent during childhood was somewhat
different between groups (p<0.05). Pa-
tients with benign tumors had in greater
number of cases father as a favorite par-
ent during childhood (13.73% vs. 1.17%).
The aim of this study was to compare
differences in sexual behavior between
patients with benign and malignant
breast tumors. Table 4 presents a com-
parison of the examinees attitudes re-
garding sexual life before and after treat-
ment of breast tumors. It should be
mentioned that period referred as »before
treatment« covers the time before the di-
agnosis of breast tumor was established.
Our investigation showed that 88.24% of
patients with benign tumors and 78.47%
with malignant tumors were satisfied with
their sexual life before diagnosis and treat-
ment of disease. Only 1.96% patients with
benign tumors did not have sexual inter-
course, however 14.12% of patients with
malignant tumors did not have sexual in-
tercourse, which was a statistically sig-
nificant difference (p<0.01). This differ-
ence can be explained by different age of
onset of these two types of breast tumors
(see table 1). After the treatment, the at-
titudes toward sexual life remained the
same in 61.77% and 44.71% of patients
with benign and malignant tumors, re-
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TABLE 3
DISTRIBUTION OF PATIENTS ACCORDING TO FAVORITE PARENT DURING CHILDHOOD AND





Favorite parent during childhood*
Mother 40 (39.21) 32 (37.65)
Father 14 (13.73) 1 (1.17)
Both 27 (26.47) 24 (28.24)
Brothers and sisters 14 (13.73) 20 (23.53)
No one 7 (6.86) 8 (9.41)
Favorite parent during puberty
Mother 40 (39.21) 28 (32.94)
Father 7 (6.86) 1 (1.18)
Both 27 (26.47) 28 (32.94)
Brothers and sisters 14 (13.73) 20 (23.53)
No one 14 (13.73) 8 (9.41)
Attitude towards menarche
Surprise 32 (31.37) 35 (41.18)
Happiness 3 (2.94) 4 (4.70)
Unhappiness 12 (11.76) 5 (5.88)
No attitude 55 (53.93) 41 (48.24)
Attitude towards first intercourse
Nice 27 (26.73) 22 (25.88)
Painful 17 (16.83) 23 (27.06)
Unpleasant 9 (8.91) 11 (12.94)
No attitude 48 (47.53) 29 (34.12)
* p < 0.05
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TABLE 4
A COMPARISON OF THE ATTITUDES OF EXAMINEES REGARDING SEXUAL LIFE BEFORE





Attitude towards sexual life before treatment**
Satisfied with it 90 (88.24) 65 (76.47)
Unsatisfied with it 10 (9.80) 8 (9.41)
Does not have intercourse 2 (1.96) 12 (14.12)
Attitude towards sexual life after treatment**
Same 63 (61.77) 38 (44.71)
Worse 35 (34.31) 30 (35.29)
Better 2 (1.96) 3 (3.53)
Does not have intercourse 2 (1.96) 14 (16.47)
Reason of dysfunction in patients' sexual life
after treatment
Fear of pain 11 (31.43) 6 (20.00)
Painful intercourse 8 (22.86) 3 (10.00)
Impossible penetration 2 (5.71) 3 (10.00)
Other 14 (40.00) 18 (60.00)
** p < 0.01
TABLE 5
A COMPARISON OF THE ATTITUDES OF EXAMINEES REGARDING THEIR PARTNERS





Behavior of the partner after treatment
Better 38 (48.72) 29 (52.73)
Worse 2 (2.56) 3 (5.45)
Same 38 (48.72) 23 (41.82)
Talking about sexual life with partner before treatment
Yes 46 (54.76) 30 (52.63)
No 38 (45.24) 27 (47.37)
Talking about sexual life with partner after treatment
Yes 43 (52.44) 32 (55.17)
No 39 (47.56) 26 (44.83)
Do you feel men fare better in life than women?
Yes 61 (59.80) 57 (67.06)
No 1 (0.98) 1 (1.18)
Same 40 (39.22) 27 (31.76)
Are you satisfied with your marriage?
Yes 60 (76.92) 42 (76.37)
No 4 (5.13) 3 (5.45)
Partly 14 (17.95) 10 (18.18)
spectively. Deterioration in sexual life ex-
perienced 36.27% of patients with benign
tumors and 51.76% of patients with ma-
lignant tumor (p<0.01). These results in-
dicate the existence of sexual dysfunctions
following breast tumor treatment, which
is more prominent in group of patients
with malignant tumors. The main reason
of sex life impairment in both groups was
distortion of body image perception (this
reason was the most common under term
»other«), followed by fear of pain. This is
consistent with fact that emotional and
psychological factors are responsible for
majority of problems in sexual function-
ing.
Table 5 reveals a comparison of the
examinees attitudes regarding their part-
ner’s behavior before and after treat-
ment. The supportive role of the partner
was already well recognized in the litera-
ture as a very important factor that can
facilitate psychological recovery of the pa-
tients10. Most of partners did not change
their behavior toward women with breast
tumors (48.72% for benign group and
41.82% or malignant group, p>0.05), or
they were more tender and caring (48.72%
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TABLE 6
A SURVEY OF SOME PSYCHOLOGICAL IMPLICATIONS FOLLOWING TREATMENT OF





Attitude towards your body after treatment (body image)**
Same as it was before treatment 76 (74.51) 50 (58.82)
Different than it was before 26 (25.49) 35 (41.18)
Do you feel more frightened for your health after treatment?
More 47 (46.08) 36 (42.35)
Less 12 (11.76) 7 (8.24)
Same 43 (42.16) 42 (49.41)
Is sexual life, in your opinion, important after treatment?
Yes 55 (53.92) 33 (38.82)
No 12 (11.76) 9 (10.59)
I do not know 35 (34.31) 43 (50.59)
Would you recommend this kind of treatment to other women?
Yes 90 (88.24) 77 (90.59)
No 1 (0.98) 0
I do not know 11 (10.78) 8 (9.41)
What kind of consultation regarding sex life after treatment
would you recommend to other women?
Women and her physician 17 (16.67) 18 (21.18)
Women, her husband and her physician 22 (21.57) 17 (20.00)
Try, and if there are problems than consultation 42 (41.18) 30 (35.29)
I do not know 21 (20.58) 20 (23.53)
Have you ever use hormonal replacement therapy?
Yes 13 (12.75) 7 (8.24)
No 89 (87.25) 78 (91.76)
**p<0.01
for benign group and 52.73% or malig-
nant group, p>0.05). In table 5 we can
also see that majority of patients were
satisfied with their marriage (76.92% for
benign group and 76.37% or malignant
group, p>0.05) and breast tumor did not
influence on talking about sex life, re-
gardless of its histology (p>0.05). Major-
ity of women in both groups (59.80% and
67.06%) feel that men fare better in life
(p>0.05).
Table 6 shows some psychological im-
plications following treatment of breast
tumors. A great amount of women in both
groups felt certain change in her »body
image«, but in greater extent in malig-
nant group (41.18% vs. 25.49%), and this
was statistically significant (p<0.05). This
can be explained by more invasive ap-
proach to treatment and use of adjuvant
chemotherapy. Less than one half of pa-
tients in both group felt more frightened
for their life after treatment (46.08% in
benign and 42.35% in malignant group).
It is very interesting that 53.92% of pa-
tients feel that sex life is important after
benign, and 38.82% after malignant
breast tumor, but this difference was not
statistically significant. Patients in both
groups would recommend same kind of
treatment to other women with similar
diagnosis. From our results we can see
that patients in this study do not recog-
nize need for consultation with their phy-
sician regarding sex life after treatment
of tumor (41.18% for benign and 35.29%
in malignant group). Most of patients in
this study did not use hormone replace-
ment therapy.
Discussion
There is an evolving body of research
and clinical literature that illuminates
the variety of psychological and sexual
sequels of a breast cancer diagnosis and
treatment, and the interventions that
may aid in recovery11,12. The inability to
recognize and treat these sexual distur-
bances is a common and serious problem.
Cosmetics plays an important role in
sexual functioning after treatment of
breast cancer. Surgical, radiotherapeutic,
chemotherapeutic and host factors may
influence cosmetic outcome13. Surgical
factors include the extent of surgical re-
section, formation of scar, and extent of
axillary dissection. Recently developed
procedures like sentinel lymph-node bi-
opsy and breast-conservation therapy,
have greatly reduced poor cosmetic out-
come after surgery. Radiation therapy
factors include doses of radiation to the
whole breast, overall duration of therapy,
type and dose of boost and beam energy.
These risk factors have tried to be elimi-
nated by fractionation of radiation doses
and by usage of brachytherapy or elec-
tron-beam boost therapy. Chemotherapy
risk factors include cytotoxic agents used
and different combination of drugs. Now-
days, however, many new, potentially ef-
fective chemotherapeutic drugs are un-
der development, and we have to wait to
see their effect on cosmetic and sexual
functioning of women with breast cancer.
Host factors include size and shape of the
breast, age, race, compliance with care,
concurrent medical conditions (such as
diabetes, coronary disease, cerebrovascu-
lar disease). In this paper we have dem-
onstrated that treatment of breast tumor,
whether benign or malignant, influence
perception of one owns body. This percep-
tion is, however, in greater extent dis-
torted in malignant group, which is con-
sequence of more invasive treatment.
This can be explained by greater use of
chemotherapy in this group of patients.
Young-McCaughan showed that women
treated with chemotherapy were 5.7 times
more likely than women not treated with
chemotherapy to report vaginal dryness,
3.0 times more likely to report decreased
libido, 5.5 times more likely to report
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dyspareunia, and 7.1 times more likely to
report difficulty achieving orgasm14.
Bukovi} investigated changes in sex-
ual life in 83 patients with gynecological
tumors. The main changes were noted re-
garding satisfaction with sexual life in
general, enjoyment during the inter-
course, frequency of the intercourse and
orgasm15. The same author emphasized
the need for consultations regarding sex
life after diagnosis of gynecological tu-
mor16. However, this study did not con-
firm these results, but this can be attrib-
uted to different populations questioned
in these two studies. Population in this
study was mainly from rural areas and of
lower education. However, healthcare pro-
fessionals must acknowledge the scope of
the impact of cancer treatment on sexual-
ity, include such information as part of
the informed consent process, and pro-
vide appropriate education and referral17.
Oncology professionals should initiate
communication about sexual difficulties,
perform comprehensive assessments, and
educate and counsel patients about the
management of these difficulties18.
Chemotherapy has been shown to be
associated with short and long-term ef-
fects on sexual functioning and quality of
life in breast cancer19. Endocrine therapy
in breast cancer appears not to affect lev-
els of sexual functioning, although this
may depend on the age of the woman14.
Sexual self-schema appears to be an im-
portant concept in predicting sexual dys-
function19. More research is still required
to identify how sexual dysfunction is af-
fected in different groups of women and
how best to help women who experience
sexual difficulties.
Thors reviews studies in which sexual
functioning in breast cancer survivors
has been investigated. With regard to
treatment effects, evidence suggests that
breast cancer patients who undergo che-
motherapy are at high risk for sexual
dysfunction after treatment18. In con-
trast, findings indicate that no significant
difference exist in sexuality between wo-
men treated by lumpectomy and those
treated by mastectomy20.
Breast cancer has the potential to be
most devastating to the sexual function
and self-esteem of premenopausal women,
and younger women with breast cancer
have more severe emotional distress than
older cohorts21,22. Systemic treatment
(adjuvant chemotherapy) disrupts sexual
function by causing premature menopau-
se, vaginal dryness, loss of bleeding, loss
of sexual sensations, and loss of woman-
hood21,23,24. Research on mastectomy ver-
sus breast conservation across all ages of
women has demonstrated that general
psychological distress, marital satisfac-
tion, and overall sexual frequency and
function do not differ between the two
treatment groups, but women with breast
conservation do rate their body image
more highly and are more comfortable
with nudity and breast caressing21. This
is supported by this study, where it can be
seen that women with benign breast tu-
mor rate their body higher, as a conse-
quence of less invasive treatment (no che-
motherapy and radical operations). Futu-
re studies should use rigorous methodol-
ogy and focus on the impact of premature
menopause and the effectiveness of sex-
ual rehabilitation for younger women21.
Previous reports suggest that prob-
lems in sexual functioning may be com-
mon among long-term (> 5 years) breast
cancer survivors. To investigate this issue
further, Broeckel examined the charac-
teristics and correlates of sexual func-
tioning in women diagnosed with breast
cancer at least 5 years previously and
treated with adjuvant chemotherapy and
in an age-matched comparison group of
women with no history of cancer. Com-
pared with women with no history of can-
cer, long-term breast cancer survivors re-
ported worse sexual functioning (p =
0.01), characterized by greater lack of
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sexual interest, inability to relax and en-
joy sex, difficulty becoming aroused, and
difficulty achieving an orgasm. Additional
analyses indicated that severity of vagi-
nal dryness was significantly (p = 0.05)
related to poorer sexual functioning among
long-term breast cancer survivors23.
The main limitation of this study was
that results are collected from women
born in relatively small part of Croatia,
and they do not necessarily apply to other
populations. It also must not be forgotten
that patients with benign breast tumors
are younger, and that this can be partly
responsible for better sexual function in
younger women. However, we have clearly
showed the existence of sexual dysfunc-
tions following breast tumor treatment,
and that main reason of impairment was
distortion of body image perception (this
was greater in malignant group). It is
also noteworthy to mention that most of
the patients are aware of importance of
sexuality after treatment of breast tumor.
Further studies are necessary to evaluate
individual impact of chemotherapy and
invasive surgery on sexual function in
women with malignant tumors, and to
evaluate impact of different chemothe-
rapeutics that are used for treatment of
breast cancer on sexual function.
Conclusion
This study revealed different prob-
lems and difficulties regarding sexual life
in women with benign and malignant
breast cancer. Our study showed that
sexual functioning after treatment of
breast tumors is worsened, especially in
women with malignant type of tumors.
The role of the partner is referred to as
very positive and supporting. Patients
also felt some differences in »body image«
perception, but greater amount of pa-
tients felt these differences in malignant
group of patients. From our results we
can see that patients in this study do not
recognize need for consultation with their
physician regarding sex life after treat-
ment of tumor, which can be explained by
level of education and rural living place.
Sexual life was recognized as an impor-
tant part of life after treatment of breast
tumors. Regarding above mentioned, can
be concluded that considerable amount o
attention should be given to psychological
aspects of recovery that can improve
prognosis and quality of life in general.
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RAZLIKE U SEKSUALNOM FUNKCIONIRANJU IZME\U PACIJENTICA
SA DOBRO]UDNIM I ZLO]UDNIM NOVOTVORINAMA DOJKE
S A @ E T A K
Cilj ove studije je odrediti postoje li razlike u spolnom `ivotu kod pacijentica nakon
dobro}udnog i zlo}udnog tumora dojke. Pacijentice koje su prije 1 do 10 godina lije~ene
od tumora dojke u Op}oj bolnici Po`ega su u razdoblju od sije~nja 2001. i svibnja 2003.
ispunile upitnik koji je posebno osmi{ljen za ovo istra`ivanje. Pogor{anje spolnog `i-
vota primijetilo je 36.27% pacijentica s dobro}udnim tumorom dojke i 51.76% pacijen-
tica sa zlo}udnim tumorom dojke (p<0.01). Naj~e{}i razlog navedenog pogor{anja bila
je promjena percepcije o vlastitom tijelu. Ve}ina pacijentica nije primijetila promjene u
pona{anju kod svojih partnera (48.72% u dobro}udnoj skupini i 41.82% u zlo}udnoj
skupini, p>0.05). Ve}ina je pacijentica promijenila sliku o vlastitom tijelu, vi{e u sku-
pini pacijentica sa zlo}udnom novotvorinom (41.18% vs. 25.49%), (p<0.05). Pacijentice
u ovoj studiji nisu prepoznale potrebu za konzultacijom s lije~nikom u vezi spolnog
`ivota nakon lije~enja novotvorine dojke (41.18% u dobro}udnoj skupini i 35.29% u zlo-
}udnoj). Iz gore navedenog, mo`e se zaklju~iti da je potrebno vi{e pa`nje posvetiti psi-
holo{kom aspektu lije~enja novotvorine dojke {to mo`e pobolj{ati prognozu i kvalitetu
`ivota op}enito.
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